Topoisomerase mutations in trovafloxacin-resistant Staphylococcus aureus

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 8, 1998, Pages 2122-2124

  Fitzgibbon, Joseph E ^a   John, Joseph F ^a   Delucia, Jennifer L ^a   Dubin, Donald T ^a,b  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE; LEVOFLOXACIN; METICILLIN; OXACILLIN; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATION; CONTROLLED STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0031948111     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.8.2122     Document Type: Article

References (18)

1. Acar, J. F., and F. W. Goldstein. 1997. Trends in bacterial resistance to fluoroquinolones. Clin. Infect. Dis. 24(Suppl. 1):S67-S73.
2. Bonilla, H. F., L. T. Zarins, S. F. Bradley, and C. A. Kauffman. 1996. Susceptibility of ciprofloxacin-resistant staphylococci and enterococci to trovafloxacin. Diagn. Microbiol. Infect. Dis. 26:17-21.
3. Chaudhry, A. Z., C. C. Knapp, J. Sierra-Madero, and J. A. Washington. 1990. Antistaphylococcal activities of sparfloxacin (CI-978; AT-4140), ofloxacin, and ciprofloxacin. Antimicrob. Agents Chemother. 34:1843-1845.
4. Desuchi, T., A. Fukuoka, M. Yasuda, M. Nakano, S. Ozeki, E. Kanematsu, Y. Nishino, S. Ishihara, Y. Ban, and Y. Kawada. 1997. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae. Antimicrob. Agents Chemother. 41:699-701.
5. Drlica, K., and X. Zhao. 1997. DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol. Mol. Biol. Rev. 61:377-392.
6. Endtz, H. P., J. W. Mouton, J. G. den Hollander, N. van den Braak, and H. A. Verbrugh. 1997. Comparative in vitro activities of trovafloxacin (CP-99,219) against 445 gram-positive isolates from patients with endocarditis and those with other bloodstream infections. Antimicrob. Agents Chemother. 41:1146-1149.
7. Ferrero, L., B. Cameron, and J. Crouzet. 1995. Analysis of gyrA and grlA mutations in stepwise-selected ciprofloxacin-resistant mutants of Staphylococcus aureus. Antimicrob. Agents Chemother. 39:1554-1558.
8. Ferrero, L., B. Cameron, B. Manse, D. Lagneaux, J. Crouzet, A. Famechon, and F. Blanche. 1994. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol. Microbiol. 13:641-653.
9. Heisig, P. 1996. Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 40:879-885.
10. Jones, R. N. 1994. Preliminary interpretive criteria for in vitro susceptibility testing of CP-99219 by dilution and disk diffusion methods. Diagn. Microbiol. Infect. Dis. 20:167-170.
11. Margerrison, E. E., R. Hopewell, and L. M. Fisher. 1992. Nucleotide sequence of the Staphylococcus aureus gyrB-gyrA locus encoding the DNA gyrase A and B proteins. J. Bacteriol. 174:1596-1603.
12. National Committee for Clinical Laboratory Standards. 1996. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. M7-A3. National Committee for Clinical Laboratory Standards, Villanova, Pa.
13. Novick, R. 1967. Properties of a cryptic high-frequency transducing phage in Staphylococcus aureus. Virology 33:155-166.
14. Sefton, A. M., J. P. Maskell, A. M. Rafay, A. Whiley, and J. D. Williams. 1997. The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria. J. Antimicrob. Chemother. 39(Suppl. B):57-62.
15. Takahata, M., M. Yonezawa, S. Kurose, N. Futakuchi, N. Matsubara, Y. Watanabe, and H. Narita. 1996. Mutations in the gyrA and grlA genes of quinolone-resistant clinical isolates of methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. 38:543-546.
16. Takenouchi, T., C. Ishii, M. Sugawara, Y. Tokue, and S. Ohya. 1995. Incidence of various gyrA mutants in 451 Staphylococcus aureus strains isolated in Japan and their susceptibilities to 10 fluoroquinolones. Antimicrob. Agents Chemother. 39:1414-1418.
17. Tanaka, M., Y. Onodera, Y. Ushida, K. Sato, and I. Hayakawa. 1997. Inhibitory activities of quinolones against gyrase and topoisomerase IV purified from Staphylococcus aureus. Antimicrob. Agents Chemother. 41:2362-2366.
18. Yamagishi, J., T. Kojima, Y. Oyamada, K. Fujimoto, H. Hattori, S. Nakamura, and M. Inoue. 1996. Alterations in the DNA topoisomerase IV grlA gene responsible for quinolone resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1157-1163.